Core Viewpoint - CSL is expanding its plasma therapy manufacturing facility in Kankakee, Illinois, with a new investment of $1.5 billion, building on over $3 billion already invested in U.S. operations since 2018, which will create at least 300 new jobs and enhance production capabilities for plasma-derived therapies and albumin [1][2]. Group 1: Investment and Job Creation - The new $1.5 billion investment will create at least 300 new pharmaceutical roles and approximately 800 construction and related jobs in the local community [2]. - Since 2018, CSL has invested more than $3 billion in its U.S. operations, creating over 6,500 new American jobs and bringing its total U.S. headcount to nearly 19,000, representing about 60% of CSL's global workforce [2]. Group 2: Manufacturing Expansion and Technology - The Kankakee expansion is expected to be operational by 2031 and will incorporate CSL's Horizon 2 manufacturing process, a patented technology that enhances production yield of immunoglobulin from the same amount of plasma [1][2]. - The expansion aims to improve plasma efficiency and strengthen CSL's U.S. network to support the sustained growth of lifesaving therapies [1]. Group 3: Community and Economic Impact - Local officials, including Illinois Governor JB Pritzker, emphasized the expansion's role in supporting patients and strengthening the regional economy [1]. - The investment is seen as a significant boost to Illinois' life sciences manufacturing sector, reinforcing the state's position as a hub for advanced biologics manufacturing [2]. Group 4: Importance of Plasma-derived Therapies - Plasma-derived therapies treat serious and rare diseases, including hemophilia and primary immunodeficiency, and are essential for many emergency and life-threatening conditions [2]. - The production of plasma-derived medicines is complex and costly, requiring long-term investment and specialized expertise [2].

Financial Data and Key Metrics Changes - In fiscal year 2025, the company generated EUR 468 million in free cash flow, an increase of over EUR 200 million year-over-year, reflecting a focus on capital discipline [4] - Revenue reached EUR 7,524 million, representing a 7% increase over the previous year and a 9.1% increase on a like-for-like basis [4] - Adjusted EBITDA reached EUR 1,825 million, a 5.6% year-over-year increase, with a like-for-like increase of close to 12% [5][34] - The leverage ratio improved to 4.2 times, a reduction of 0.4 times from the previous year [5][38] Business Line Data and Key Metrics Changes - The Biopharma segment grew 8.4% for the year on a reported basis and 10.9% on a like-for-like basis, driven by the immunoglobulin franchise, which saw a 14.7% year-over-year increase [11] - Albumin revenues declined by 5.1% year-over-year due to market pressures in China, although the company outperformed the market through its partnership with Shanghai RAAS [15] - The Alpha-1 and specialty proteins portfolio saw a full-year growth of 1.4% or 3.8% on a like-for-like basis [16] Market Data and Key Metrics Changes - In the U.S., the company stands as the only scale plasma company with a fully integrated end-to-end value chain, which is crucial for the IgG market [9] - In Canada, the share of IG self-sufficiency increased from 15% to around 30% in 2025, with plans for further expansion [26] - The strategic partnership in Egypt has achieved EMA approval for Egyptian-sourced plasma, marking a significant milestone for the company [27] Company Strategy and Development Direction - The company aims to prioritize profitability and cash flow generation while reducing leverage, focusing on key projects in Egypt and Canada [9] - The local-for-local business model has proven resilient against macroeconomic challenges, allowing the company to navigate tariff impacts effectively [8] - The company is committed to enhancing its vertical integration and self-sufficiency in key markets, which is expected to provide a competitive advantage [22][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and fundamentals, emphasizing the resilience of the plasma industry amid geopolitical shifts [10][53] - The focus for 2026 will be on margin expansion and controlled growth, with a clear strategy to balance growth across IG and albumin [49] - The company is optimistic about the long-term potential of its strategic partnerships and the ability to meet evolving market demands [32][53] Other Important Information - The company achieved a significant credit rating improvement, with S&P upgrading its rating from B flat stable to BB- stable [45] - The company plans to refinance its 2027 maturities, with preparations already in advanced stages [46] Q&A Session Summary Question: Is 2026 a specific year where growth differs from capital market targets? - Management clarified that revenue growth is not a priority for 2026, focusing instead on optimizing EBITDA quality and leveraging market share gains in the U.S. [56][57] Question: What is the potential EBITDA guidance for 2026? - Management indicated that the EBITDA guidance for 2026 could be around EUR 1.9 billion to EUR 1.97 billion, depending on margin assumptions [63][64] Question: What are the internal levers to improve profitability? - Management explained that the focus is on balancing growth in IG and albumin while driving efficiencies in manufacturing and plasma collection [68][72] Question: What is the status of the Haema BPC buyback? - Management stated that the timing of the buyback will be determined by the board, with potential execution in 2026 or 2027 [73]

FY 2025 Results February 26, 2026 FY 2025 Results - 1 - Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended and restated from time to ...

Summary of Expert Call on China's Blood Products Industry Industry Overview - The expert call focused on the blood product industry in China, particularly the dynamics surrounding albumin and intravenous immunoglobulin (IVIG) sales and inventory levels [2][7]. Key Points Inventory and Sales Dynamics - In Q425, there was a significant increase in shipments from producers, leading to higher channel inventory, particularly for albumin, where some small distributors hold over six months of inventory compared to two months for IVIG [2][8]. - The in-hospital sales volume of albumin has decreased by 30-40% following the full rollout of DRG/DIP policies in late 2025, which has tightened control over albumin prescriptions [3][8]. - The share of in-hospital sales has shifted from 60% to approximately 50%, indicating a more balanced distribution between in-hospital and ex-hospital sales channels [3][10]. Pricing Trends - In-hospital prices for albumin have fallen by about 10%, while ex-hospital prices have seen a larger decline due to intense competition [3][8]. - The in-hospital sales volume of IVIG has dropped by around 20%, but it is expected to have decent long-term growth potential due to its wide range of applications and lower per-capita use compared to overseas markets [3][11]. Plasma Collection and Industry Consolidation - Plasma collection volume has shown steady annual growth of 5-10%, although the approval process for new plasma stations remains stringent [4][16]. - The industry is expected to consolidate from over 20 companies to fewer than 10 in the long term, driven by mergers and acquisitions (M&A) as larger companies leverage advanced technology for production [4][18]. Future Outlook - The expert anticipates that the blood products industry will remain under pressure throughout 2026 due to high inventory levels and stringent control measures [2][9]. - There is a potential for a quarter-over-quarter recovery in Q226, but overall shipments are expected to be pressured year-over-year in Q126 [2][9]. Regulatory and Competitive Landscape - The rollout of value-based pricing (VBP) policies may impact albumin pricing significantly, with the possibility of tiered or region-based coverage [19]. - Domestic companies are currently stocking plasma, and while there is a possibility of import restrictions in the future, the current demand for imports remains strong [13][15]. Risks - Key risks identified for the healthcare industry include unexpected price cuts from government programs, intensified competition, and regulatory changes that could adversely affect market dynamics [20]. Additional Insights - The expert noted that while there is no efficacy difference between domestic and imported products, foreign companies have better penetration in hospitals due to established relationships [14]. - The growth trend in plasma collection is expected to continue, with leading companies potentially increasing their volume through M&A activities [16][18]. This summary encapsulates the critical insights from the expert call regarding the current state and future outlook of China's blood products industry, highlighting both opportunities and challenges.

Summary of the Conference Call on China's Plasma Industry Industry Overview - The conference call focused on the plasma product industry in China, specifically the performance of seven A-share listed plasma product companies in Q3 2025 [1][2]. Key Points Revenue Growth - The combined revenue growth of the seven listed plasma product companies turned positive, attributed to three M&A transactions since Q4 2024 [1]. - However, on a comparable basis, revenue growth remains negative for these companies [1]. Albumin Market Dynamics - Lot release volumes of albumin increased by 6% in the first nine months of 2025 [9]. - Despite the increase in volume, terminal prices of albumin have continued to decline, indicating an oversupply situation [1][19]. Policy Impact - Demand for plasma products is negatively affected by policy factors such as DRG/DIP reform, tighter medical insurance cost control, and enhanced monitoring of off-label use [1]. Company-Specific Performance - Hualan's Q3 2025 revenue was Rmb1,581 million, down 14% year-over-year, and net profit was Rmb269 million, down 44% year-over-year, missing Goldman Sachs estimates [25]. - The decline in Hualan's performance was attributed to seasonal fluctuations in influenza vaccine sales and lower-than-expected plasma product sales [25]. New Product Launch - Oryzogen's rice-derived recombinant albumin was approved for market launch, with production costs expected to decrease as capacity expands [19][20]. - The seven listed companies noted differences between plasma-derived and recombinant albumin, particularly in immunogenicity and production costs, with plasma-derived products holding advantages [20]. Industry Consolidation - The trend of mergers and acquisitions in the plasma industry is increasing, with no new plasma product companies approved since 2001, leading to higher industry concentration [23]. - Notable M&A transactions include Boya Biopharm selling shares to China Resource and Hualan's acquisition of a subsidiary from CSL [24]. Financial Estimates and Risks - Hualan's target price was revised to Rmb18 from Rmb19, reflecting earnings revisions and industry trends [25]. - Key risks include stricter controls on albumin prescriptions, rising accounts receivable days, and intensified competition in the influenza vaccine market [30]. Additional Insights - Inventory turnover days for most listed companies declined, indicating that inventories are not currently a burden [15]. - However, accounts receivable days peaked in Q3 2025, suggesting that distributors may be taking on more inventory due to sales pressure [16]. This summary encapsulates the critical insights from the conference call regarding the plasma product industry in China, highlighting both opportunities and challenges faced by the companies involved.

Core Viewpoint - CSL Limited has experienced a significant decline in share price, dropping nearly 15% following its latest AGM, primarily due to a forecasted decline in U.S. influenza vaccination rates by 12% [1][2] Financial Performance - The company anticipates a revenue decline in the influenza segment by a number in the mid-teens, which is worse than the previously expected high single-digit growth [2] - Overall revenue growth is now projected at 2-3% year-over-year, down from an earlier estimate of 4-5% [2] - Profit after tax growth is also revised down to 4-7%, reduced from 7-10% [2] Market Challenges - Reduced demand for albumin in China is impacting the company's financials, with CSL aiming to limit the effects to the first half of FY26 [2] - Policy changes in China have made domestic albumin cheaper, affecting CSL's export strategy [2] Management Insights - CSL's Chair, Brian McNamee, acknowledged the frustrations of shareholders regarding the company's performance and the need for change [3] - CEO Dr. Paul McKenzie reaffirmed confidence in the core business and mentioned ongoing efforts to streamline operations for growth [4] Workforce and Cost Management - The company employs over 29,000 staff globally, which may be impacted by a cost-cutting program hinted at during the AGM [4]

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: The conference call primarily discusses the healthcare sector in China, particularly the medical technology (Medtech), in vitro diagnostics (IVD), retail pharmacies, hospitals, vaccines, and insulin markets [1][2]. Core Insights and Arguments Medtech - **Key Areas of Focus**: 1. Progress of capital equipment value-based procurement (VBP) and the trade-in policy [1] 2. Channel destocking trends [1] 3. Import substitution trends post-VBP, including intraocular lenses (IOLs) and IVD [1] - **VBP Impact**: The June bidding value data showed a year-on-year growth rate of 49%, but a month-on-month decline of 3%, indicating lower unit prices due to VBP [10]. IVD Market - **Weak Demand**: The IVD sector continues to face challenges, with a projected 20% year-on-year decline in the CLIA reagent market size for 2025 [19]. - **AmoyDx Performance**: AmoyDx is expected to grow against the trend due to its strong presence in compliant in-hospital sales channels, benefiting from the anti-corruption campaign [21]. Insulin Market - **Domestic Substitution**: The insulin industry has seen significant growth, particularly for insulin analogs from companies like Gan & Lee and THDB, which reported rapid revenue growth in 1Q25 [22]. Retail Pharmacies - **Market Pressure**: Retail pharmacies are under pressure due to strict reimbursement policies and weak consumer spending. However, there is a potential market-clearing trend expected by year-end [31]. Hospitals - **New Product Feedback**: Hospitals are seeing new product introductions, such as the new version of SMILE surgery and new PIOL products, which are expected to drive consumption recovery [1]. Vaccine Market - **Anti-Corruption Campaign**: The ongoing anti-corruption campaign within the CDC system is impacting vaccine demand and distribution channels [1]. Financial Performance and Estimates Earnings Revisions - **Mindray**: Annual earnings estimates revised down by 2.1% to 5.0% for 2025E-27E due to industry headwinds in medical equipment and IVD [2][37]. - **United Imaging**: Revenue and earnings forecasts adjusted down to reflect lower-than-expected bidding data [39]. - **SNIBE**: Earnings estimates revised down by 1.4% to 7.1% for 2025E-27E due to policy headwinds in the IVD sector [40]. Revenue Growth Expectations - **High Growth Companies**: THDB and Gan & Lee are expected to achieve the highest revenue growth due to a low base from VBP renewal in 2Q24 [6]. - **Mindray's Decline**: Mindray's China business is expected to decline by 26% year-on-year in 2Q25 due to IVD weakness [9]. Other Important Insights - **Trade-in Policy Concerns**: The trade-in stimulus fund is expected to run out, leading to a decline in applications and a reduced stimulus effect in the second half of 2025 [10]. - **Market Dynamics**: The healthcare market is experiencing a shift with increasing government support for procurement and a focus on innovative products [47][48]. Conclusion - The healthcare sector in China is facing various challenges, including policy headwinds, weak demand in certain segments, and the impact of ongoing reforms. However, there are also opportunities for growth, particularly in innovative products and domestic substitution trends. Companies like AmoyDx, Gan & Lee, and THDB are positioned to benefit from these trends, while others like Mindray and SNIBE are facing headwinds that may impact their performance in the near term.